Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Lymphoma Clinical Trials

115 recruiting trials for Lymphoma. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
115
Total Trials
115
Recruiting Now
8
Phase 3 Trials
10
Sponsors

Recruiting Trials

RECRUITINGNCT05635266

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and...

Sponsor: Sanguine BiosciencesEnrolling: 200001 location
RECRUITINGPhase 1 / Phase 2NCT02332668

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma...

Researchers are looking for new ways to treat children with different types of melanoma (skin cancer), solid tumors, and lymphomas (blood cancers) that are any of these: *...

Sponsor: Merck Sharp & Dohme LLCEnrolling: 37017 locations
RECRUITINGPhase 1NCT06326463

CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies

The study participant has one of the following blood cancers: acute myelogenous leukemia (AML)/myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (B-ALL, T-ALL) or...

Sponsor: St. Jude Children's Research HospitalEnrolling: 181 location
RECRUITINGPhase 2NCT03314974

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or,...

Sponsor: Masonic Cancer Center, University of MinnesotaEnrolling: 3001 location
RECRUITINGPhase 1 / Phase 2NCT07052695

Mosunetuzumab for CLL MRD Clearance

The goal of this study is to test mosunetuzumab given alone or in combination with a Bruton tyrosine kinase inhibitor (BTKi, such as ibrutinib, acalabrutinib, zanubrutinib, or...

Sponsor: Inhye AhnEnrolling: 402 locations
RECRUITINGNCT05011045

Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies

This study assesses neurocognitive outcomes after receiving radiation therapy to the brain (whole brain radiation therapy) in patients with blood cancers (hematologic...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 1001 location
RECRUITINGNCT05873322

Glucose Intolerance and Diabetes Related to Treatment With Steroids and PEG- Asparaginase in Children and Adolescents...

The overall survival of acute lymphoblastic leukemia (ALL) and lymphoma in children and adolescents is above 90%. The survival rate has increased significantly during the last...

Sponsor: Aarhus University HospitalEnrolling: 1001 location
RECRUITINGNCT03568266

Pharmacogenomics of Asparaginase Induced Hepatotoxicity

This pilot trial studies the impact of genetic information on developing liver damage caused by asparaginase in participants with newly diagnosed acute lymphoblastic leukemia....

Sponsor: University of Southern CaliforniaEnrolling: 5001 location
RECRUITINGPhase 3NCT05602194

Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma

This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with...

Sponsor: Children's Oncology GroupEnrolling: 44020 locations
RECRUITINGPhase 1 / Phase 2NCT04110301

MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)

This phase 1b/2 trial studies the safety and best dose of lenalidomide when given together with MIL62 and how well this combination works in treating patients with...

Sponsor: Beijing Mabworks Biotech Co., Ltd.Enrolling: 531 location
RECRUITINGPhase 2NCT05168930

Zanubrutinib and Venetoclax in CLL (ZANU-VEN)

This study is being done to test the effectiveness of zanubrutinib in combination with venetoclax in participants with previously treated chronic lymphocytic leukemia (CLL) or...

Sponsor: Dana-Farber Cancer InstituteEnrolling: 454 locations
RECRUITINGPhase 1 / Phase 2NCT06768905

Study of IOMAB-ACT Followed by CAR-T Cell Therapy for Patients Relapsed or Refractory (Diffuse Large B-cell Lymphoma

This study is being done to determine the safety, efficacy and tolerability of a single 50 mCi dose of 131I-Apamistamab given prior to CAR-T cell infusion in patients with...

Sponsor: University of Texas Southwestern Medical CenterEnrolling: 301 location
RECRUITINGPhase 2 / Phase 3NCT04442022

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With...

The purpose of this Phase 2/3 study is to evaluate efficacy and safety of the combination of selinexor and R-GDP (SR-GDP) in patients with RR DLBCL who are not intended to receive...

Sponsor: Karyopharm Therapeutics IncEnrolling: 50120 locations
RECRUITINGNCT06664229

Development of Pressure Sensor Based Dementia and Fall Prevention Program for Older Adults

The goal of this intervention program is to test the effectiveness of pressure sensor based dementia and fall prevention program for improving cognitive and physical functions of...

Sponsor: Sunmi SongEnrolling: 2051 location
RECRUITINGPhase 1NCT04162353

BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma

This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19 cCAR in patients with relapsed and/or refractory...

Sponsor: iCell Gene TherapeuticsEnrolling: 122 locations
RECRUITINGPhase 1 / Phase 2NCT05869279

Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia

This is a single arm, open-label, multi-center, phase I/II study to determine the engraftment, safety and clinical activity of allogeneic CARCIK-CD19 cells in adult and pediatric...

Sponsor: Fondazione Matilde Tettamanti Menotti De Marchi OnlusEnrolling: 291 location
RECRUITINGPhase 3NCT07083154

GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)

The LIGHT-COG study is a 76-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial. A total of 420 type 2 diabetes patients with early...

Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolEnrolling: 4208 locations
RECRUITINGPhase 1NCT07121946

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

This study is a first-in-human (FIH), Phase 1, multicenter, open-label study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and evaluate the...

Sponsor: LTZ Therapeutics, Inc.Enrolling: 425 locations
RECRUITINGPhase 1NCT06860594

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or...

This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has...

Sponsor: National Cancer Institute (NCI)Enrolling: 3020 locations
RECRUITINGPhase 3NCT06082102

Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients...

Efficacy and Safety of Orelabrutinib Combined with Rituximab versus Lenalidomide Combined with Rituximab in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.Enrolling: 32419 locations
RECRUITINGPhase 2NCT06300528

Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

The purpose of this clinical trial is to learn if the study drug pemigatinib is effective in treating patients with relapsed or refractory B-cell non-Hodgkin lymphomas.

Sponsor: University of UtahEnrolling: 271 location
RECRUITINGPhase 2NCT05436223

Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma

A Phase Ⅱ Clinical Study Evaluating the Efficacy and Safety of Human CD19 Targeted T Cells Injection (CD19 CAR-T) Therapy for R/R B-NHL. Patients will be given a conditioning...

Sponsor: Hrain Biotechnology Co., Ltd.Enrolling: 1001 location
RECRUITINGPhase 2NCT07254754

Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma

Single-arm, open-label, multicenter, phase II trial aiming to include approximately 45 patients over 24 months. Patients will receive axicabtagene ciloleucel infusion and will be...

Sponsor: Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaEnrolling: 4515 locations
RECRUITINGPhase 1 / Phase 2NCT06880913

Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL

To evaluate the efficacy and safety of Nanobody-Based CD19/CD22 Tandem Dual Chimeric Antigen Receptor (CAR) T-cell therapy in patients with relapsed or refractory B-ALL

Sponsor: Peking University People's HospitalEnrolling: 501 location
RECRUITINGPhase 2NCT06158399

AZA Combined With RCHOP in P53-mutated DLBCL.

To evaluate the efficacy and adverse effects of Azacitidine in combination with R-CHOP (ARCHOP) for the treatment of TP53-mutated previously untreated Diffuse large B-cell lymphoma

Sponsor: The First Affiliated Hospital of Xiamen UniversityEnrolling: 521 location
RECRUITINGNCT02872987

GMALL Registry and Collection of Biomaterial: Prospective Data Collection Regarding Diagnosis, Treatment and Outcome of...

The GMALL registry serves the purpose of ALL research and quality assurance. The Registry collects data about diagnostics, treatment and outcome of Adult ALL Patients in the...

Sponsor: Goethe UniversityEnrolling: 1000020 locations
RECRUITINGPhase 2NCT07153796

A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity...

This is a single arm open-label phase 2 trial to study the safety and efficacy of SC Blinatumomab in combination with low-intensity chemotherapy for older or unfit patients with...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 601 location
RECRUITINGNCT04006561

Prospective Neurobehavioral Functions in Newly-diagnosed Patients With Primary CNS Lymphoma Treated With...

Primary central nervous system lymphoma (PCNSL) is an uncommon disease. Conventional treatment has consisted of either whole-brain radiation therapy (WBRT) or methotrexate...

Sponsor: Chang Gung Memorial HospitalEnrolling: 361 location
RECRUITINGPhase 3NCT07377578

A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle...

Mantle cell lymphoma (MCL) is an aggressive yet often indolent type of B-cell non-Hodgkin lymphoma (NHL). Rocbrutinib (LP-168) is a novel, highly selective, fourth-generation...

Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD.Enrolling: 3942 locations
RECRUITINGEarly Phase 1NCT06393335

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory...

A Study of Metabolically Armed CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory CD19-positive B cell Hematological Malignancies

Sponsor: The Children's Hospital of Zhejiang University School of MedicineEnrolling: 361 location
RECRUITINGPhase 2NCT06846489

Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell...

This is a single- arm, open-label, multicenter, phase II study to evaluate Acalabrutinib plus Rituximab for the treatment of elderly or low- to intermediate-risk younger untreated...

Sponsor: Sun Yat-sen UniversityEnrolling: 501 location
RECRUITINGNCT04613388

Registry Study of Proton Radiotherapy in Lymphoma

The aim is to record and document a mediastinal PT and the corresponding follow-up data (effectiveness and side effects). General recommendations for planning and feasibility are...

Sponsor: University Hospital HeidelbergEnrolling: 2001 location
RECRUITINGPhase 1NCT06447376

Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab

The goal of this clinical trial is to is to determine the safety, feasibility and efficacy of siltuximab prophylaxis of cytokine release syndrome and neurotoxicity occurring after...

Sponsor: Taylor BrooksEnrolling: 201 location
RECRUITINGPhase 1NCT05156203

Safety and Tolerability Study for T-1301 Capsules to Treat Advanced Solid Tumors

T-1301 is a novel small-molecule inhibitor of multiple kinases being developed as an oral drug for the treatment of advanced solid tumors. The nonclinical study results...

Sponsor: Taivex Therapeutics CorporationEnrolling: 303 locations
RECRUITINGPhase 2NCT06387121

Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL

In the treatment of Ph-negative (Ph-) B-cell acute lymphoblastic leukemia (B-ALL) among adult patients, therapeutic outcomes remain suboptimal despite advances in chemotherapy and...

Sponsor: Institute of Hematology & Blood Diseases Hospital, ChinaEnrolling: 531 location
RECRUITINGPhase 1NCT06830031

Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma

This study is to investigate the safety and tolerability of C402-CD19-CAR treatment in subjects with relapsed or refractory large B-cell lymphoma and further determine the...

Sponsor: Shanghai Exuma Biotechnology Ltd.Enrolling: 181 location
RECRUITINGNCT06002828

Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors

This study examines the impact of social and genetic factors on outcomes in adolescent and young adult (AYA) cancer survivors of Hodgkin or non-Hodgkin lymphoma. Compared to both...

Sponsor: ECOG-ACRIN Cancer Research GroupEnrolling: 200020 locations
RECRUITINGPhase 2NCT06554600

A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of...

This is a prospective, multicenter, single-arm, open phase II study to explore the efficacy and safety of Zanubrutinib in combination with Polatuzumab Vedotin, bendamustine, and...

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang UniversityEnrolling: 361 location
RECRUITINGNCT07030400

Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma

The study aims to improve our understanding of how quality of life, fatigue, and symptoms change over 2 years when participants are treated for chronic lymphocytic leukemia or...

Sponsor: H. Lee Moffitt Cancer Center and Research InstituteEnrolling: 1001 location
RECRUITINGNCT06004011

AYAHIV Role-based Responsibilities for Oncology-focused Workforce (ARROW)

Adolescents and young adults living with HIV experience higher premature mortality from cancer than their uninfected peers. In Zambia, because of multilevel barriers,...

Sponsor: ImplenomicsEnrolling: 41001 location
RECRUITINGPhase 4NCT02670564

ALL SCTped FORUM - Pharmacogenomic Study (add-on Study)

Pharmacogenomics (PG) offers the opportunity to individualize treatment according to patient genetic variations which influence activity of enzyme metabolizing or acting in the...

Sponsor: Swiss Pediatric Oncology GroupEnrolling: 10004 locations
RECRUITINGPhase 3NCT04269902

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia...

This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk...

Sponsor: National Cancer Institute (NCI)Enrolling: 24720 locations
RECRUITINGNCT06526065

Molecular Mechanisms in Malignant Lymphoma- Predict (MMML Predict)

The trial aims at the construction and validation of an accurate, affordable and simple prognostic tool to be used in everyday clinical practice, which allows the early and...

Sponsor: University Medical Center GoettingenEnrolling: 5001 location
RECRUITINGPhase 1NCT07143929

To Observe the CD7-targeted CAR-T Therapy in the Treatment of r/r PTCL

To observe the efficacy and safety of CD7-targeted chimeric antigen receptor T cells in the treatment of refractory or relapsed PTCL.

Sponsor: Peking University People's HospitalEnrolling: 181 location
RECRUITINGPhase 1 / Phase 2NCT06735495

CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors

This study is a multi-center, open, prospective single-arm clinical study of patients with relapsed / refractory B cell hematological tumors to evaluate the safety and efficacy of...

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyEnrolling: 801 location
RECRUITINGPhase 2NCT06701357

CR-CHOP+X in Previously Untreated DEL

This is a prospective, single-arm, open-label phase II clinical trial that evaluates the efficacy and safety of CR-CHOP regimen combined with different targeted drugs based on...

Sponsor: Ruijin HospitalEnrolling: 491 location
RECRUITINGPhase 2NCT06566807

Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma

This is a multi-center, prospective study. The main purpose is to evaluate the efficacy and safety of Orelabrutinib combined with Obinutuzumab for previously untreated MZL.

Sponsor: Huai'an First People's HospitalEnrolling: 511 location
RECRUITINGPhase 1NCT06026319

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side effects when treated...

Sponsor: Marcela V. Maus, M.D.,Ph.D.Enrolling: 241 location
RECRUITINGPhase 1 / Phase 2NCT01371630

Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia

This phase I/II trial studies the side effects and best dose of inotuzumab ozogamicin and to see how well it works when given together with combination chemotherapy in treating...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 2761 location
RECRUITINGPhase 3NCT03643276

Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

The understanding of acute lymphoblastic leukemia (ALL) in childhood and adolescence has largely changed due to extensive genetic research in recent years: ALL is now considered...

Sponsor: Martin SchrappeEnrolling: 500020 locations

Showing 50 of 115 trials.Search all Lymphoma trials